Loading company…
SOL Bio develops exosome-based cancer diagnostic technology and tests.
Founded in 2020 and based in Seoul, SOL Bio develops exosome diagnostic technology for early cancer detection. Its ExoMAIN test uses an exosome isolation kit to detect 13 major cancer types. The company plans to commercialize diagnostic equipment and license its technology to overseas medical device companies.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in